Neonatal exposure to soy isoflavones at levels similar to that of infants fed soy protein formula resulted in higher bone mineral density (BMD), improved bone structure, and greater bone strength at young adulthood in female CD-1 mice (1,2).
Introduction
Epidemiological studies indicate that the incidence of osteoporosis-related fractures is significantly lower in Asian women than in Western women (3) (4) (5) (6) (7) . However, this health advantage diminishes as Asian women adopt a Western lifestyle (8) . Soybased foods such as tofu, miso, and tempeh provide a rich source of soy isoflavones (9) and are commonly consumed in Asia. Soy isoflavones are bioactive compounds structurally similar to 17b-estradiol, an essential mediator for normal bone metabolism (10) . Thus, the lower incidence of fragility fractures among Asian women may in part be explained by their lifelong exposure to higher concentrations of soy isoflavones than most Western women (11) . Human intervention trials that have administered soy isoflavones to postmenopausal women in North America and Europe have, for the most part, reported modest or no effect of soy isoflavones at preserving bone mineral density (BMD) 4 at the hip or spine (12) (13) (14) (15) (16) (17) (18) (19) (20) . The lack of agreement among the epidemiological studies and clinical studies may be at least partly explained by the timing of exposure to soy isoflavones in the life cycle. Critical stages of development may exist in which exposure to soy isoflavones results in long-term benefits to bone health. For example, the fetal-origin hypothesis states that early events, mainly those of metabolic nature, are memorized by the developing organism through fetal and neonatal programming (21) . The United Nations Standing Committee on Nutrition has proposed that a window of opportunity exists from prepregnancy to 24 mo of a child's life during which nutrition can affect the structural and functional development of an organism (22) . This phenomenon can be referred to as nutritional programming and describes the effects that occur when an external stimuli (i.e. soy isoflavones) during a sensitive developmental period or window results in a permanent or long-term change in the structure or function of an organism (23) . Therefore, nutritional programming may provide a prevention strategy for development of chronic diseases such as osteoporosis (24) .
It is possible that infants fed soy protein formula may experience nutritional programming with respect to bone metabolism. On the basis of body weight, infants fed soy infant formula are consuming markedly higher levels of soy isoflavones than even adults that consume a typical Asian or plant-based diet. The use of soy protein formula was first proposed in the late 1920s for babies with cow milk intolerance (25) , and the American Academy of Pediatrics (26) recommends soy protein formulas as a safe and effective alternative for providing adequate nutrition for normal growth and development of term infants who are lactose intolerant or whose nutritional needs are not being met by maternal breast milk. The use of soy protein formula varies on a global scale. The percentage of infants consuming soy protein formula within the first year of life varies from~5 to 30% worldwide (26) (27) (28) .
Nutritional programming of bone metabolism by isoflavones has been studied using the CD-1 mouse model in which offspring were administered soy isoflavones during the first 5 d of life at a ratio and amount that mimics exposure of human infants fed soy protein formula (1, 2, 29) . Female offspring exposed to soy isoflavones had higher BMD and improved structure at the femur and lumbar vertebrae (LV) at 4 mo of age, the time when maximal bone mass is established in this mouse strain (1, 2, 30) . In utero exposure to soy isoflavones did not result in nutritional programming of bone metabolism (29) , indicating that the neonatal period of life may be a critical window of development for favorably modulating bone metabolism in the CD-1 mouse model. Importantly, the improvements in bone quality and quantity observed with neonatal isoflavone exposure translated into greater bone strength at these 2 skeletal sites that differ in the proportion of cortical and trabecular bone. In contrast, males exposed to soy isoflavones did not exhibit significant benefits or adverse effects at the femur or lumbar spine, suggesting that early exposure to soy isoflavones may be sex specific. Building on these previous findings, we repeated the aforementioned protocol (2) but ovariectomized or orchidectomized mice at 4 mo of age and studied them to 8 mo of age. The primary objective of this study was to determine whether the higher BMD, improved bone structure, and stronger bones at adulthood (4 mo of age) provide protection against the deterioration of bone tissue that occurs after cessation of gonadal sex steroid production in females and male mice.
Methods
Mice and treatment. Seven-week-old male and female CD-1 mice (Charles River Laboratories) were bred harem style. Distilled water and diet (AIN93G, Dyets) consumed ad libitum were provided every 2-3 d (31 , positive control) treatment. Treatment was administered via a single subcutaneous injection from postnatal d (PND) 1 through 5. In rodents, the first 5 d of life represents a window during which estradiol production is minimal and in humans this window extends to 4 mo of life (32, 33) . The DES dose was chosen as a positive control, because it has previously been shown to improve bone metabolism in mice exposed to treatment for the first 5 d of life (1, 2, 34) . The combination of daidzein and genistein was chosen to mimic the quantity and ratio of each isoflavone in soy protein infant formulas and results in similar serum levels of isoflavones as infants consuming soy formula (2).
Pups remained with mothers until weaning (PND 21) and were subsequently housed according to gender with 4 mice per cage. The control diet (AIN93G, Dyets) was provided every 2-3 d and body weight was measured once weekly. At 4 mo of age, mice were ovariectomized (females) or orchidectomized (males). At 8 mo of age, mice were killed using carbon dioxide followed by cervical dislocation. Femurs and LV1-LV3 were cleaned of soft tissue and stored at 2808C. All experimental procedures followed the policies set out by the Canadian Council on Animal Care (35) and were approved by the University Animal Ethics Committee, University of Toronto.
Area, bone mineral content, and BMD of the (LV1-LV3) and left femur. Intact LV1-LV3 and left femurs were placed on a plastic tray and scanned in air at room temperature using dual energy X-ray absorptiometry (pSabre, Orthometrix) and a specialized software program (Host Software version 3.9.4; Scanner Software version: 1.2.0) at a speed of 2 mm × min 21 and at a resolution of 0.01 mm 3 0.01 mm (2).
Biomechanical strength testing. The biomechanical strength properties of the LV2 (compression fracture) and right femur (femur neck fracture, femur midpoint fracture) were measured by compression testing and 3-point bending, respectively, using a materials testing system (Model 4442, Intron) and specialized software (Series IX Automated Materials tester, version 8.15.00) as previously described (1,2,36).
Radiographs of LV4 and whole right femur. Radiographs of LV4 and the right femur were taken to allow a visual representation of bone mineral using a dental X-ray machine (Sirona Heliodent DS, model no. 4684606 D3302). The X-ray dose was 60 kVp (tube voltage) and 7 mA (tube current) with an exposure time of 0.08 s.
Microarchitecture of LV4 and femoral neck. Microcomputed tomography was used to assess trabecular structure of LV4 and femoral neck. We assessed bone microarchitecture in females only, because our bone density and biomechanical stress testing data revealed that exposure to soy isoflavones has a profound effect only in females, with no significant effects observed in males. For each scan, an LV4 or a femur was placed inside a polymethylmethacrylate holder filled with distilled water and scanned with a microtomography system (MicroCT40, Scanco Medical) (2). The X-ray source was set at 70k Vp (tube voltage) and 114 mA (tube current). The specimens were scanned in highresolution mode with an X, Y, and Z resolution of 6 mm and acquisition files were obtained at 1000 projections with 2048 samples each (per 1808 of rotation), 08 angle increment, 300 ms of integration time, and 1 frame averaging. Each scanned image was composed of 800-1200 axial-cut slices that were 6 mm thick. For femoral neck analysis, the region of interest (ROI) was defined from the top of the growth plate to the narrowest part of the femoral shaft. For LV analyses, the total length of LV4 was measured and an ROI was chosen to represent a region of 200 slices at the midpoint of the bone. Within the ROI, the quantification of trabecular bone and particulate material volumes (in mm 3 ) was possible through the segmentation of materials using different threshold values, which were determined by analyzing the gray-level distribution. Measurements of trabecular integrity included bone volume/total volume (BV/TV 3 100; %), trabecular thickness (Tb.Th; mm), trabecular number (Tb.N; mm 21 ), and trabecular separation (Tb.Sp; mm) (2).
Statistical analyses. Statistical analyses were performed using SigmaStat (version 3.5, Jandel Scientific). Data are expressed as mean 6 SEM. Repeated measures 2-way ANOVA followed by a Student-NewmanKeul's (SNK) post hoc test were used to analyze changes in body weight at 4-wk intervals throughout the study. One-way ANOVA followed by a SNK post hoc test was used to analyze trabecular bone parameters in female mice. For all other measures, 2-way ANOVA was used with gender and treatment as the main effects, and interaction effects (gender 3 treatment) were assessed. For data that did not follow a normal distribution (femoral area and BMD, femoral neck yield load, femoral midpoint peak load, yield load, and stiffness), a Kruskal-Wallis 2-way ANOVA on ranks followed by a SNK post hoc test was used to determine differences among groups. Significance was determined as P # 0.05.
Results
Body weight. Body weight did not differ among groups at birth (PND 0) or after the 5-d intervention (PND 5) (data not shown).
At wk 4 (time near weaning), the body weight of the DES-treated females was lower (P , 0.05) than that of females exposed to soy isoflavones or control (Fig. 1A) . Females treated with soy isoflavones had a higher body weight on wk 28 and 32 than the female CON group (P , 0.05). DES-treated females had higher body weight than the female CON group from wk 8 to 32. DEStreated males had a lower body weight than male CON or DG group at all time points except wk 8 (Fig. 1B) . There was an overall gender 3 treatment effect on body weight. CON and DG-treated males had a higher (P , 0.001) body weight at wk 4, 8, 12, 16, 20 , and 24 than CON and DG-treated females. DEStreated males had a lower (P , 0.05) body weight at wk 16, 20, 24, 28, and 32 than DES-treated females.
Area, bone mineral content, and BMD of intact LV1-LV3 and peak load of LV2. The area of LV1-LV3 did not differ among groups ( Table 1) . Females had higher bone mineral content (BMC) (P , 0.001) and BMD (P , 0.001) of LV1-LV3 than males and there was an overall effect of treatment (Table 1) . Among females, the isoflavone-treated group had higher BMC (P = 0.004) and BMD (P , 0.001) than the control or DES group (Table 1) . The greater bone mineral of LV with DG was also evident from radiographs of representative samples (Supplemental Fig. 1) .
Area, BMC, and BMD of LV1-LV3 or peak load of LV2 in males did not differ (Table 1 ). There was an interaction of gender 3 treatment for peak load (Table 1) . Females treated with DG had a higher peak load (P = 0.014) of LV2 than all other treatment groups (Table 1) . DES-treated males had a significantly lower (P , 0.001) peak load of LV2 than DES-treated females (Table 1) .
Area, BMC, BMD, and biomechanical strength properties of the femur. Femoral area was greater (P , 0.001) among males compared with females. Femoral BMC (P = 0.013) and BMD (P , 0.05) were greater among DES-treated females compared with DES-treated males ( Table 2) . Between gender, femoral area was lower (P , 0.001) among the DES groups compared with the CON groups, whereas treatment with soy isoflavones had no effect. Males treated with DES had lower (P = 0.037) BMC than all other treatment groups. Females treated with DG had higher (P = 0.039) femoral BMD compared with CON, while DES had intermediary effects. The greater femoral bone mineral with DG was also evident from radiographs of representative samples (Supplemental Fig. 1 ).
There was an effect of gender on femoral midpoint yield load (P = 0.003) and stiffness (P = 0.012) ( Table 2) , with females having higher values than males. Peak load at the femoral midpoint was higher (P = 0.013) among the DG-treated females than the CON females ( Table 2) . At the femoral neck, yield load (P = 0.032) and stiffness (P = 0.008) were higher among males compared with females (Table 2 ). There was an interaction between gender and treatment for peak load at the femoral neck. DES-treated males had lower peak load (P = 0.015) at the femoral neck than CON or DG-treated males. Stiffness was lower (P = 0.016) among DES-treated males compared with all other treatment groups ( Table 2) .
Microarchitecture of LV4 and femoral neck. Females treated with DG and DES had higher (P = 0.019) Tb.Th at LV4 compared with CON ( Table 3 ) and visual inspection suggested an improved trabecular network with DG or DES ( Fig. 2A) . Treatment with DES resulted in higher (P = 0.037) Tb.N at LV4 compared with CON, and DG did not differ from the CON and DES groups (Table 3) . No treatment effects were observed for BV/TV or Tb.Sp at LV4. At the femoral neck, there were no treatment effects for BV/TV, Tb.Th, Tb.N, or Tb.Sp (Table 3) . Visual inspection suggested that females treated with DG or DES had greater cortical thickness compared with the CON group (Fig. 2B) .
Discussion
In female CD-1 mice, exposure to soy isoflavones during the first 5 d of life, at a ratio equivalent to the amount of soy isoflavones consumed by infants fed soy formula, protects against deterioration of bone tissue after the decline of endogenous estrogen production. Multiple outcomes of bone health, including functional and structural indices of LV-BMC, BMD, peak load, and Tb.Th-were improved with early isoflavone intervention. In contrast, bone outcomes in males were neither improved nor adversely modulated by early intervention with soy isoflavones. These gender-specific findings are consistent with previous investigation (2) using the same mouse model and protocol in which mice were studied until 4 mo of life, when maximal BMC is achieved in this mouse strain (30) . Exposure to daidzein and/ or genistein from PND 1 to 5 improved bone mineral, strength, and microarchitecture at the femur and LV in female CD-1 mice at 4 mo of age but had minimal effects on bone development in male mice (2) . Orchidectomy resulted in a more profound loss of bone tissue than ovariectomy. To estimate the percent loss of BMD that occurred during the 4 mo after orchidectomy or ovariectomy (performed at age 4 mo), the lumbar spine BMD of 4-mo-old intact CD-1 mice obtained from 2 separate studies (2,30) was compared with that of 8-mo-old orchidectomized and ovariectomized mice from the present study. The 8-mo-old orchidectomized males experienced a 20% reduction in BMD at the lumbar spine compared with 10% in ovariectomized females. This finding is consistent with previous literature. Koustein et al. (37) reported that 6-mo-old orchidectomized male mice had 2 times more apoptosis of osteoblasts at the lumbar spine than ovariectomized female mice of a similar age (28 vs. 14%). The higher rate of apoptosis of osteoblasts in orchidectomized mice was associated with a reduction (;12%) in bone strength at the lumbar spine (37) .
Inclusion of a sham-operated control would have allowed for direct comparisons with gonadal intact groups, but the primary objective of this study was to determine whether the higher BMD and improved bone structure and strength at adulthood (4 mo of age) provide protection against the deterioration of bone tissue that occurs after cessation of gonadal sex steroid production in females and male mice. At both 4 and 8 mo of age, the relative differences among the CON, DG, and DES groups for key outcomes were similar, particularly among females. Compared with CON, the DG and DES groups had a LV BMD that was 1.3 and 1.2 times higher at 4 mo and 1.2 and 1.1 times higher at 8 mo of age, respectively. Moreover, DG and DES groups had a LV peak load that was 1.3 and 1.4 times higher at 4 mo and 1.6 and 1.2 times higher at 8 mo of age, respectively, compared with CON. These findings suggest that improved bone health at 4 mo of age likely had a marked role in preserving bone tissue after gonadal removal.
Piglets fed soy-based formula from PND 2 to 25 or 35 had greater tibial BMC, BMD, and trabecular bone volume than sow-fed piglets (38) . These structural improvements were associated with osteoblast proliferation and differentiation from bone marrow cells and an upregulation of markers of bone formation (i.e. alkaline phosphatase and osteocalcin) and genes including alkaline phosphatase and bone morphogenic protein. Moreover, markers of bone resorption, i.e. C-telopeptide, and genes that stimulate bone resorption, i.e. RANKL, were downregulated. These findings suggest that soy formula has positive effects on both bone modeling and remodeling. Although pigs are a good model for early infant bone development, studies investigating long-term programming are impeded by the fact that pigs do not reach peak bone mass until 3 y of age and are extremely large (39) . In addition, pigs are not good models of postmenopausal bone loss after estrogen withdrawal (39) . Thus, to answer the objective of the present study, a rodent model was chosen.
Early exposure to isoflavones resulted in higher body weight from 28 wk through 32 wk of age but not at earlier stages of development. This finding is consistent with our published data that studied CD-1 mice to 16 wk of age (2) . However, others have reported higher body weight at 12 and 16 wk of age in the same mouse model when higher doses of isoflavones (50 mg × kg body weight 21 × d 21 vs. the dose of 7 mg × kg body weight 21 × d 21 used in this study) were administered from PND 1 to 5 (40) . Therefore, the dose of isoflavone exposure may program the time when female mice begin to gain weight. Another study showed that female Wistar rats exposed to isoflavones (40 mg × kg body weight 21 × d
21
) during gestation and lactation exhibit an increase in body weight at 24 mo of age (41) , indicating that this stage of development programs body weight gain in other animal models than that used in this study. In contrast, studies that have investigated isoflavone effects on body composition in ovariectomized juvenile and adult rodents have reported lower body weight, fat pad weight, and lipoprotein lipase mRNA expression (42) (43) (44) (45) . For example, ovariectomized male and female mice exposed to genistein (20 or 80 mg × kg 21 × d 21 ) experienced a 37-57% decrease in adipose tissue weight due to a dose-responsive decrease in adipocyte circumference and subcutaneous (inguinal) and visceral (parametrial and renal) fat pad weight (44) . Other studies have shown that genistein regulates fat mass by binding to estrogen receptors and modulating the expression of genes that regulate lipolysis, lipogenesis, and adipocyte metabolism (46, 47) . However, if estrogen receptors are not present, genistein does not alter body composition (48) . Similarly, clinical studies have shown that isoflavone supplementation reduced body weight in premenopausal female athletes (49) and postmenopausal women (50, 51) and isoflavone supplementation was shown to modulate body fat distribution by decreasing total body fat and increasing lean body mass (50) . Findings from adult humans and animals have in part been explained by the ability of genistein to bind to estrogen receptors and induce estrogen-like responses in adipose tissue, but the effects observed in neonatal mice have not been characterized. It is possible that female body weight changes induced by soy isoflavones depend on endogenous estrogen concentrations and the overall opportunity to bind to estrogen receptors.
According to studies using estrogen receptor knockout mice, the lack of response of adipose tissue to estrogen causes the mouse to gain weight at sexual maturity (45) . Exposure to isoflavones during early development also causes the mice to gain weight in later life (37, 38) , whereas isoflavone exposure at sexual maturity promotes weight loss (39) (40) (41) (42) (46) (47) (48) . Therefore, exposure to isoflavones during early development may modulate the imprinting effects of estrogen receptor genes in adipose tissue, resulting in estrogen receptors that are less responsive to estrogen during adulthood.
Neonatal exposure to soy isoflavones did not affect male body weight, whereas exposure to DES was characterized by lower body weights at almost all the measured time points. This effect of DES was previously reported (52) . Contrary to our findings, Ronis et al. (47) showed that male Sprague-Dawley rats exposed to isoflavones (80 mg × kg 21 × d 21 ) from PND 15 to 33 via a soy protein isolate diet had reduced body weight at PND 33. Thus, the effects of soy isoflavones on body weight may be time, dose, and sex dependent as initial exposure to isoflavone occurred at weaning, the outcomes were assessed prior to sexual maturity, and the treatment dose was .10-fold higher than the dose used in the present study.
In conclusion, our study findings suggest that targeting the first 5 d of rodent life may provide a window for inducing longterm programming effects on skeletal development. Short-term neonatal exposure to soy isoflavones provides protection against the deterioration of bone tissue in ovariectomized females but not orchidectomized males. Further research is required to elucidate the mechanisms by which isoflavones mediate this effect on bone metabolism in females. There is some evidence that administration of synthetic estrogen (DES) or genistein during early life alters the responsiveness of the pituitary, which could indirectly modulate bone metabolism (53) . It is also possible that isoflavones modulate bone metabolism through epigenetic changes, specifically DNA methylation of genes that modulate bone cell metabolism. Findings from this study form the basis for investigating the effects of soy infant formula on bone metabolism in adult life.
